洛匹那韦/利托那韦联合秋水仙碱治疗非重症COVID-19肺炎住院患者的随机对照试验方案结构化摘要
本研究为前瞻性、随机、双盲、平行对照试验,计划纳入80例非重症COVID-19肺炎住院患者,比较洛匹那韦/利托那韦联合秋水仙碱与单用洛匹那韦/利托那韦的疗效。主要结局为治疗14天后临床改善时间和肺CT评分变化,次要结局包括炎症指标、氧疗需求和住院时长。
要点
- 秋水仙碱可能通过抗炎机制改善非重症COVID-19肺炎。
- 试验采用1:1随机双盲设计,计划样本量80例。
- 主要结局为14天临床改善时间与肺CT评分变化。
核心结论
- 研究旨在评估秋水仙碱在非重症住院COVID-19患者中的抗炎效果。
研究设计与样本
- 前瞻性、随机(1:1)、双盲、平行组设计。
- 计划纳入80例鼻咽拭子RT-PCR阳性且CT符合COVID-19肺炎的住院患者,不需插管或侵入性氧疗。
- 招募自伊朗德黑兰Labbafinejad医疗中心住院患者。
- 随机化使用在线工具GraphPad进行分配。
- 受试者和结局评估者设盲。
关键数值与推荐
- 主要结局:治疗14天后临床改善时间和肺CT评分变化。
- 次要结局:治疗14天后C反应蛋白×中性粒细胞与淋巴细胞比值、白介素-6、丙二醛水平降低;需要补充氧气的患者比例;平均住院时长。
- 干预组:洛匹那韦/利托那韦+秋水仙碱1.5 mg负荷量后0.5 mg每日两次口服;对照组:单用洛匹那韦/利托那韦。
- 两组均接受基于CDC和WHO指南及伊朗国家共识的最佳治疗,包括相同剂量的洛匹那韦/利托那韦、抗生素、微量元素和抗氧化剂。
- 排除标准:对秋水仙碱过敏、肝衰竭、eGFR<30 ml/min/1.73m2、肾移植受者、使用地高辛、QTc>450毫秒。
临床怎么用
- 本方案为研究设计,尚不能直接指导临床实践。
- 若试验证实有效,秋水仙碱可能作为非重症COVID-19肺炎的辅助抗炎治疗。
局限性
- 样本量较小(80例),可能影响统计效能。
- 单中心研究,结果外推性受限。
- 招募预计于2020年5月30日完成,实际进度可能受疫情影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients. TRIAL DESIGN: Prospective, randomized (1:1 ratio), double blind study with parallel group design. PARTICIPANTS: Hospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation. EXCLUSION CRITERIA: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m2 (by the CKD-EPI Creatinine Equation for Glomerular Filtration Rate (GFR) which estimates GFR based on serum creatinine. ; kidney transplant recipients, using Digoxin, QTc >450 msec. Participants will be recruited from inpatients at Labbafinejad Meidcal Center , Tehran, Iran. INTERVENTION AND COMPARATOR: Eligible enrolled patients will be randomized into two groups. Group A will receive the antiretroviral Lopinavir/Ritonavir (Kaletra) while group B will receive Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally. All patients in both groups will receive the same amounts of essential minerals, vitamins as antioxidants, and antibiotics. Patients of both groups will be treated under optimal treatment based on the CDC and WHO guidelines and national consensus proposed in Iran including the same dosages of Lopinavir/Ritonavir, antibiotics, trace elements and antioxidants while only in group-B patients Colchicine will be added on top of this protocol. MAIN OUTCOMES: Primary: Time for clinical improvement and lung CT score changes 14 days after treatment. Secondary: 14 days after treatment - C-Reactive Protein test x Neutrophil to Lymphocyte Ratio , Interleukin-6, malondialdehyde (MDA) levels reduction - Percentage of patients who require supplemental Oxygen - Mean hospital stay length RANDOMISATION: Patients will be allocated to each group (ratio 1:1) by using an online randomization tool: http://www.graphpad.com/quickcalcs/index.cfm BLINDING (MASKING): This will be a double-blind study in which participants and those assessing the final outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients. TRIAL STATUS: Recruitment is ongoing. Recruitment began on 20/03/2020 and the date by which the recruitment is anticipated to be completed is 30/05/2020. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04360980, registered 24/04/2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Dalili N, Kashefizadeh A, Nafar M, et al. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial. Trials. 2020. PMID: 32503620. doi:10.1186/s13063-020-04455-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。